Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk factors for stroke and systemic embolic events. A 5-year follow-up study. [EXTENSION OF 700034457]

Trial Profile

Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk factors for stroke and systemic embolic events. A 5-year follow-up study. [EXTENSION OF 700034457]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs AZD 0837 (Primary) ; Warfarin
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Oct 2015 Status changed from completed to discontinued as per European Clinical Trials Database record.
    • 13 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top